UK Supreme Court’s Actavis ruling finds balance for pharma and generics: lawyers
The UK Supreme Court’s ruling in Actavis v Icos is likely to satisfy pharmaceutical and generics companies, according to lawyers involved in the case
The UK’s highest court yesterday affirmed that a patent licensed from former biotech company Icos to Eli Lilly for the erectile dysfunction (ED) drug Cialis (tadalafil) is invalid.
In their ruling, the five justices unanimously dismissed an appeal from...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.